logo
Share SHARE
FONT-SIZE Plus   Neg

Aeterna: Final Phase 3 Results Show AEZS-130 Safe, Effective In Diagnosing AGHD

Aeterna Zentaris Inc. (AEZS, AEZ.TO) said that final Phase 3 results for its oral ghrelin agonist, AEZS-130, show that the drug is safe and effective in diagnosing adult growth hormone deficiency, or AGHD.

The multicenter open label study was originally designed as a cross-over trial of AEZS-130 vs growth hormone-releasing hormone (GHRH)+L-Arginine (ARG) in AGHD patients and in controls, matched for body mass index, estrogen status, gender and age. After 43 AGHD patients and 10 controls had been tested, GHRH became unavailable. The study was completed by testing 10 more AGHD patients and 38 controls with AEZS-130 alone.

The objective of the clinical trial was to determine the efficacy and safety of AEZS-130 in the diagnosis of AGHD.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Seattle police caught an alleged car thief by remotely locking him inside the stolen BMW 550i with the help of the automaker. The Seattle Police Department said in its blog that the incident took place in Seattle in November. United Airlines' new ticket option called 'Basic Economy,' which would require travelers to pay extra fees for using overhead bins, has been termed by New York Senator Charles Schumer as "one of the most restrictive policies on airline passengers seen in a long time." Schumer said that United Airlines should scrap its plan. United Airlines' new ticket option called 'Basic Economy,' which would require travelers to pay extra fees for using overhead bins, has been termed by New York Senator Charles Schumer as "one of the most restrictive policies on airline passengers seen in a long time." Schumer said that United Airlines should scrap its plan.
comments powered by Disqus
Follow RTT